Multiple shRNAs targeting ASMA and MKL1 showed the strongest inhibition of ASMA in dermal fibroblasts from 2 different SSc donors, confirming the ability of the assay to identify strong regulators of the myofibroblast phenotype (Fig. 4A). This evidence concerns the gene ACTA1 and systemic sclerosis.